(INDV) Indivior Ordinary Shares - Ratings and Ratios
Suboxone, Sublocade, Subutex, Opvee
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 49.9% |
| Value at Risk 5%th | 67.9% |
| Relative Tail Risk | -17.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.27 |
| Alpha | 174.99 |
| CAGR/Max DD | 0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.509 |
| Beta | 0.666 |
| Beta Downside | 0.668 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.89% |
| Mean DD | 30.11% |
| Median DD | 28.82% |
Description: INDV Indivior Ordinary Shares November 10, 2025
Indivior PLC (NASDAQ: INDV) is a specialty biopharma focused on developing, manufacturing, and commercializing buprenorphine-based therapies for opioid dependence and related substance-use disorders across the United States, Europe, Canada, Australia, and other international markets.
Its flagship portfolio includes the monthly SUBLOCADE extended-release injection, SUBOXONE Film and Tablet (buprenorphine-naloxone sublingual formulations), SUBUTEX Tablet (buprenorphine monotherapy), and the OPVEE nasal spray for opioid-overdose reversal. The pipeline features INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 for moderate-to-severe OUD, and INDV-6001, a long-acting injectable being co-developed with Alar Pharmaceuticals.
In FY 2023, Indivior generated $1.04 billion in revenue, driven primarily by SUBLOCADE and SUBOXONE sales, while reporting a net loss of $145 million and maintaining $460 million of cash and marketable securities-sufficient to fund R&D through 2026 under current burn rates. The company’s growth outlook is tied to macro-drivers such as expanding Medicaid enrollment, ongoing opioid-crisis legislation that increases reimbursement for medication-assisted treatment, and a projected 6 % CAGR in the global OUD therapeutics market through 2030.
For a deeper quantitative view, consider using ValueRay’s analyst toolkit to model INDV’s cash-flow sensitivity to policy shifts and payer dynamics.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (166.0m TTM) > 0 and > 6% of Revenue (6% = 70.9m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 27.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.64% (prev -13.78%; Δ 10.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 193.4m > Net Income 166.0m (YES >=105%, WARN >=100%) |
| Net Debt (-89.0m) to EBITDA (315.0m) ratio: -0.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (129.0m) change vs 12m ago -3.41% (target <= -2.0% for YES) |
| Gross Margin 82.81% (prev 79.97%; Δ 2.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.01% (prev 80.81%; Δ 1.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.73 (EBITDA TTM 315.0m / Interest Expense TTM 52.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.19
| (A) -0.03 = (Total Current Assets 922.0m - Total Current Liabilities 965.0m) / Total Assets 1.42b |
| (B) -0.24 = Retained Earnings (Balance) -346.0m / Total Assets 1.42b |
| (C) 0.21 = EBIT TTM 298.0m / Avg Total Assets 1.44b |
| (D) -0.19 = Book Value of Equity -316.0m / Total Liabilities 1.62b |
| Total Rating: 0.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.04
| 1. Piotroski 7.0pt |
| 2. FCF Yield 3.06% |
| 3. FCF Margin 11.39% |
| 4. Debt/Equity -1.72 |
| 5. Debt/Ebitda -0.28 |
| 6. ROIC - WACC (= 633.1)% |
| 7. RoE -60.42% |
| 8. Rev. Trend 89.56% |
| 9. EPS Trend 18.92% |
What is the price of INDV shares?
Over the past week, the price has changed by +1.29%, over one month by -1.12%, over three months by +59.22% and over the past year by +202.34%.
Is INDV a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the INDV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.9 | 4.6% |
| Analysts Target Price | 37.9 | 4.6% |
| ValueRay Target Price | 40.6 | 12.2% |
INDV Fundamental Data Overview January 03, 2026
P/E Trailing = 36.6122
P/E Forward = 11.0742
P/S = 3.8016
P/B = 145.2492
Beta = 1.109
Revenue TTM = 1.18b USD
EBIT TTM = 298.0m USD
EBITDA TTM = 315.0m USD
Long Term Debt = 304.0m USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 356.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.40b USD (4.49b + Debt 356.0m - CCE 445.0m)
Interest Coverage Ratio = 5.73 (Ebit TTM 298.0m / Interest Expense TTM 52.0m)
FCF Yield = 3.06% (FCF TTM 134.5m / Enterprise Value 4.40b)
FCF Margin = 11.39% (FCF TTM 134.5m / Revenue TTM 1.18b)
Net Margin = 14.06% (Net Income TTM 166.0m / Revenue TTM 1.18b)
Gross Margin = 82.81% ((Revenue TTM 1.18b - Cost of Revenue TTM 203.0m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 82.78%)
Tobins Q-Ratio = 3.11 (Enterprise Value 4.40b / Total Assets 1.42b)
Interest Expense / Debt = 3.37% (Interest Expense 12.0m / Debt 356.0m)
Taxrate = -13.51% (negative due to tax credits) (-5.00m / 37.0m)
NOPAT = 338.3m (EBIT 298.0m * (1 - -13.51%)) [negative tax rate / tax credits]
Current Ratio = 0.96 (Total Current Assets 922.0m / Total Current Liabilities 965.0m)
Debt / Equity = -1.72 (negative equity) (Debt 356.0m / totalStockholderEquity, last quarter -207.0m)
Debt / EBITDA = -0.28 (Net Debt -89.0m / EBITDA 315.0m)
Debt / FCF = -0.66 (Net Debt -89.0m / FCF TTM 134.5m)
Total Stockholder Equity = -274.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.72% (Net Income 166.0m / Total Assets 1.42b)
RoE = -60.42% (negative equity) (Net Income TTM 166.0m / Total Stockholder Equity -274.8m)
RoCE = 1019 % (out of range, set to none) (EBIT 298.0m / Capital Employed (Equity -274.8m + L.T.Debt 304.0m))
RoIC = 641.3% (NOPAT 338.3m / Invested Capital 52.8m)
WACC = 8.13% (E(4.49b)/V(4.84b) * Re(8.47%) + D(356.0m)/V(4.84b) * Rd(3.37%) * (1-Tc(-0.14)))
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.67%
[DCF Debug] Terminal Value 68.55% ; FCFE base≈134.5m ; Y1≈88.3m ; Y5≈40.4m
Fair Price DCF = 5.91 (DCF Value 738.6m / Shares Outstanding 125.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 18.92 | EPS CAGR: -4.73% | SUE: -0.86 | # QB: 0
Revenue Correlation: 89.56 | Revenue CAGR: 9.56% | SUE: 2.25 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.65 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=2.89 | Chg30d=+0.143 | Revisions Net=+1 | Growth EPS=+24.3% | Growth Revenue=-4.7%
Additional Sources for INDV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle